Predicting Response to Perioperative Chemotherapy in Resectable Gastric Cancer: Integrating Clinical, Pathological, Molecular, and Host-Related Biomarkers

Authors

  • Rasha Haggag, Ola M. Elfarargy, Ahmad Barakat Waley, Manar Saad Mohamed Ramadan, Lamiaa M. Kamel

Keywords:

gastric cancer, perioperative chemotherapy, FLOT, treatment response

Abstract

Perioperative chemotherapy has transformed the management of locally advanced resectable gastric andgastroesophageal junction adenocarcinoma, with fluorouracil, leucovorin, oxaliplatin, and docetaxel representinga central contemporary regimen. However, therapeutic benefit is heterogeneous. Some patients achieve profound pathological regression and durable survival, whereas others experience minimal tumor response

Downloads

Download data is not yet available.

References

Cunningham D, Allum WH, Stenning SP, et al. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med. 2006;355(1):11-20. doi:10.1056/NEJMoa055531.

Downloads

Published

2024-03-15

How to Cite

Rasha Haggag, Ola M. Elfarargy, Ahmad Barakat Waley, Manar Saad Mohamed Ramadan, Lamiaa M. Kamel. (2024). Predicting Response to Perioperative Chemotherapy in Resectable Gastric Cancer: Integrating Clinical, Pathological, Molecular, and Host-Related Biomarkers . Pegem Journal of Education and Instruction, 14(3), 1333–1342. Retrieved from https://pegegog.net/index.php/pegegog/article/view/5343

Issue

Section

Article